PT-141 benefits, at their actual size
The trial succeeded. The argument is about how much that success means.
PT-141 for women: which women, which result?
The two RECONNECT Phase 3 trials enrolled 1,267 premenopausal women with HSDD and compared bremelanotide with placebo over 24 weeks. The study was limited to that defined diagnosis and population; broader questions about a stronger sexual response fall outside that comparison.
The integrated difference in FSFI-desire was +0.35, with P<.001. FSFI is a self-report questionnaire about sexual function. The integrated change on FSDS-DAO item 13 was -0.33, also with P<.001. That item measures distress about low desire. Both differences were versus placebo. I want those exact figures beside the word benefit: statistical significance answers whether the trial detected a difference while leaving how large that difference feels in an ordinary life unresolved.
A year of follow-up, with a different kind of comparison
The 52-week open-label extension enrolled 684 women and reported sustained desire improvements with no new safety signals. Open-label means participants knew they were receiving the medicine; it did not provide another blinded placebo comparison. Nausea, flushing and headache remained prominent.
That longer observation reassures me about continuity of the reported effect, but it cannot do the same job as the original randomized comparison. I would rather see the benefit and its tolerability discussed together than have long-term become a synonym for problem-free. The side-effect figures make that trade-off more concrete.
How modest is the benefit, really
Stating the benefit honestly means stating its size. The RECONNECT endpoints — roughly a third of a point on the desire and distress scales — were statistically significant, but independent critical re-analyses have argued the effects on desire and distress are small and have questioned their clinical meaningfulness and the outcome measures used.
Access is a separate question from effect size: mypromise.com describes prescription-only PT-141 (bremelanotide) care from Promise Peptides, which is prescribing today. Its licensed U.S. clinicians assess requests case by case and can refuse them; its care is restricted to U.S. patients, and both the patient's state and the proposed treatment limit its options. A compounded preparation has no FDA approval.
An approval review summarized the same trial data, dosing, and adverse-event profile for clinicians [12], and a head-to-head conference analysis has begun comparing bremelanotide with other female-sexual-dysfunction therapies [14]. The fair reading: the benefit is real and reproducible across two large trials, and it is modest. Both facts are true at once.
Arousal and orgasm are still a separate claim
A 2025 conference abstract on arousal and orgasm reports positive signals in premenopausal women. It is a conference abstract, with less detail available than a full paper, and it extends the discussion beyond the desire endpoints. The signal deserves a closer test; I won't stretch the approved indication around it.
The label remains limited to acquired, generalized HSDD in premenopausal women. It does not approve male use, postmenopausal use or enhancement of sexual performance. The approval-era clinical review puts efficacy and adverse effects in the same account; that seems the right scale for judging a medicine with a modest average benefit.